Cargando…

Homologous Recombination Repair in Biliary Tract Cancers: A Prime Target for PARP Inhibition?

SIMPLE SUMMARY: Biliary tract cancers (BTCs) are a rare but deadly group of gastrointestinal tumors that are often diagnosed in the advanced stages of disease. Despite large studies investigating optimal systemic therapy options in BTCs, current chemotherapies provide only modest benefits in overall...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Chao, Kulasekaran, Monika, Roy, Tina, Decker, Brennan, Alexander, Sonja, Margolis, Mathew, Jha, Reena C., Kupfer, Gary M., He, Aiwu R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140037/
https://www.ncbi.nlm.nih.gov/pubmed/35626165
http://dx.doi.org/10.3390/cancers14102561
_version_ 1784715001493192704
author Yin, Chao
Kulasekaran, Monika
Roy, Tina
Decker, Brennan
Alexander, Sonja
Margolis, Mathew
Jha, Reena C.
Kupfer, Gary M.
He, Aiwu R.
author_facet Yin, Chao
Kulasekaran, Monika
Roy, Tina
Decker, Brennan
Alexander, Sonja
Margolis, Mathew
Jha, Reena C.
Kupfer, Gary M.
He, Aiwu R.
author_sort Yin, Chao
collection PubMed
description SIMPLE SUMMARY: Biliary tract cancers (BTCs) are a rare but deadly group of gastrointestinal tumors that are often diagnosed in the advanced stages of disease. Despite large studies investigating optimal systemic therapy options in BTCs, current chemotherapies provide only modest benefits in overall survival. The rapidly evolving study of homologous recombination repair (HRR) as part of the broader DNA damage repair (DDR) system makes it possible to exploit deficiencies in this pathway with targeted agents such as PARP inhibitors (PARPi). We will review the rationale for PARPi use, as well as considerations for further unlocking their potential in treating BTC. ABSTRACT: Biliary tract cancers (BTCs) are a heterogeneous group of malignancies that make up ~7% of all gastrointestinal tumors. It is notably aggressive and difficult to treat; in fact, >70% of patients with BTC are diagnosed at an advanced, unresectable stage and are not amenable to curative therapy. For these patients, chemotherapy has been the mainstay treatment, providing an inadequate overall survival of less than one year. Despite the boom in targeted therapies over the past decade, only a few targeted agents have been approved in BTCs (i.e., IDH1 and FGFR inhibitors), perhaps in part due to its relatively low incidence. This review will explore current data on PARP inhibitors (PARPi) used in homologous recombination deficiency (HRD), particularly with respect to BTCs. Greater than 28% of BTC cases harbor mutations in genes involved in homologous recombination repair (HRR). We will summarize the mechanisms for PARPi and its role in synthetic lethality and describe select genes in the HRR pathway contributing to HRD. We will provide our rationale for expanding patient eligibility for PARPi use based on literature and anecdotal evidence pertaining to mutations in HRR genes, such as RAD51C, and the potential use of reliable surrogate markers of HRD.
format Online
Article
Text
id pubmed-9140037
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91400372022-05-28 Homologous Recombination Repair in Biliary Tract Cancers: A Prime Target for PARP Inhibition? Yin, Chao Kulasekaran, Monika Roy, Tina Decker, Brennan Alexander, Sonja Margolis, Mathew Jha, Reena C. Kupfer, Gary M. He, Aiwu R. Cancers (Basel) Review SIMPLE SUMMARY: Biliary tract cancers (BTCs) are a rare but deadly group of gastrointestinal tumors that are often diagnosed in the advanced stages of disease. Despite large studies investigating optimal systemic therapy options in BTCs, current chemotherapies provide only modest benefits in overall survival. The rapidly evolving study of homologous recombination repair (HRR) as part of the broader DNA damage repair (DDR) system makes it possible to exploit deficiencies in this pathway with targeted agents such as PARP inhibitors (PARPi). We will review the rationale for PARPi use, as well as considerations for further unlocking their potential in treating BTC. ABSTRACT: Biliary tract cancers (BTCs) are a heterogeneous group of malignancies that make up ~7% of all gastrointestinal tumors. It is notably aggressive and difficult to treat; in fact, >70% of patients with BTC are diagnosed at an advanced, unresectable stage and are not amenable to curative therapy. For these patients, chemotherapy has been the mainstay treatment, providing an inadequate overall survival of less than one year. Despite the boom in targeted therapies over the past decade, only a few targeted agents have been approved in BTCs (i.e., IDH1 and FGFR inhibitors), perhaps in part due to its relatively low incidence. This review will explore current data on PARP inhibitors (PARPi) used in homologous recombination deficiency (HRD), particularly with respect to BTCs. Greater than 28% of BTC cases harbor mutations in genes involved in homologous recombination repair (HRR). We will summarize the mechanisms for PARPi and its role in synthetic lethality and describe select genes in the HRR pathway contributing to HRD. We will provide our rationale for expanding patient eligibility for PARPi use based on literature and anecdotal evidence pertaining to mutations in HRR genes, such as RAD51C, and the potential use of reliable surrogate markers of HRD. MDPI 2022-05-23 /pmc/articles/PMC9140037/ /pubmed/35626165 http://dx.doi.org/10.3390/cancers14102561 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Yin, Chao
Kulasekaran, Monika
Roy, Tina
Decker, Brennan
Alexander, Sonja
Margolis, Mathew
Jha, Reena C.
Kupfer, Gary M.
He, Aiwu R.
Homologous Recombination Repair in Biliary Tract Cancers: A Prime Target for PARP Inhibition?
title Homologous Recombination Repair in Biliary Tract Cancers: A Prime Target for PARP Inhibition?
title_full Homologous Recombination Repair in Biliary Tract Cancers: A Prime Target for PARP Inhibition?
title_fullStr Homologous Recombination Repair in Biliary Tract Cancers: A Prime Target for PARP Inhibition?
title_full_unstemmed Homologous Recombination Repair in Biliary Tract Cancers: A Prime Target for PARP Inhibition?
title_short Homologous Recombination Repair in Biliary Tract Cancers: A Prime Target for PARP Inhibition?
title_sort homologous recombination repair in biliary tract cancers: a prime target for parp inhibition?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140037/
https://www.ncbi.nlm.nih.gov/pubmed/35626165
http://dx.doi.org/10.3390/cancers14102561
work_keys_str_mv AT yinchao homologousrecombinationrepairinbiliarytractcancersaprimetargetforparpinhibition
AT kulasekaranmonika homologousrecombinationrepairinbiliarytractcancersaprimetargetforparpinhibition
AT roytina homologousrecombinationrepairinbiliarytractcancersaprimetargetforparpinhibition
AT deckerbrennan homologousrecombinationrepairinbiliarytractcancersaprimetargetforparpinhibition
AT alexandersonja homologousrecombinationrepairinbiliarytractcancersaprimetargetforparpinhibition
AT margolismathew homologousrecombinationrepairinbiliarytractcancersaprimetargetforparpinhibition
AT jhareenac homologousrecombinationrepairinbiliarytractcancersaprimetargetforparpinhibition
AT kupfergarym homologousrecombinationrepairinbiliarytractcancersaprimetargetforparpinhibition
AT heaiwur homologousrecombinationrepairinbiliarytractcancersaprimetargetforparpinhibition